Daré Bioscience (NASDAQ:DARE – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $12.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 277.36% from the company’s current price.
Daré Bioscience Stock Performance
Shares of NASDAQ DARE opened at $3.18 on Tuesday. Daré Bioscience has a 52-week low of $3.05 and a 52-week high of $7.56. The firm has a 50 day moving average price of $3.55 and a two-hundred day moving average price of $3.72. The stock has a market cap of $27.67 million, a P/E ratio of -5.39 and a beta of 1.27.
Hedge Funds Weigh In On Daré Bioscience
A hedge fund recently raised its stake in Daré Bioscience stock. Renaissance Technologies LLC lifted its position in shares of Daré Bioscience, Inc. (NASDAQ:DARE – Free Report) by 2.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 778,700 shares of the biotechnology company’s stock after buying an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned about 9.25% of Daré Bioscience worth $262,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 6.70% of the company’s stock.
About Daré Bioscience
Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.
Featured Articles
- Five stocks we like better than Daré Bioscience
- What Are Dividend Challengers?
- 3 Stocks to Gain From Stockpiling Effects of the Trump Tariffs
- ETF Screener: Uses and Step-by-Step Guide
- These 3 Stocks Look to Power AI Data Centers With Natural Gas
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Shift Into Growth: Top 3 Hybrid Vehicle Makers to Invest In
Receive News & Ratings for Daré Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daré Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.